Hence, ARID1A-mutated tumours may depend on ARID1B for proliferation, suggesting a synthetic lethality combination between ARID1A and ARID1B and thus providing an opportunity for personalised targeting of cancer growth (Nagl et al., 2007; Helming et al., 2014). Here, ARID1B is linked to cancer.